Porton Launches its US Process Innovation Center

Porton Fine Chemicals, a China-based contract development and manufacturing organization (CDMO), has launched Porton USA’s Technology Center based in Cranbury, NJ, which will serve the U.S. biopharmaceutical industry, offering drug development and cross-lifecycle research, development and manufacturing solutions.

The company says it aims to deliver solutions on complex synthetic routes, next-generation processes and assembly of specialized molecules such as highly potent advanced intermediates, APIs and linker-payload components of antibody-drug conjugates (ADCs). In addition, it will support all aspects of non-GMP and GMP small molecule intermediate and API development, optimization and synthesis.

Today’s pharmaceutical company pipelines are dominated by complex molecules, posing formidable synthesis, scale-up and containment challenges, according to John Dillon, senior vice president, Porton Fine Chemicals and president, Porton USA.

“ADCs exemplify a perfect storm of manufacturing difficulties: unstable APIs and toxic intermediates requiring high containment, complex analytics, purifications and parenteral requirements,” he said. “We see high demand for this type of niche process development and manufacturing as companies seek innovative external manufacturing partners who can bring considerable experience to reliably execute such projects, many of which involve single batches representing more than f$1 million in value.”